Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus Capecitabine in HER2+ Breast Cancer Brain Metastases (PERMEATE)
NCT03691051Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2018
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in HER2-positive metastatic breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate of Intracranial Lesion at 1 year. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT03691051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691051.